Audience Unimpressed By Verve’s Base Playing
Verve’s shares dropped hard on its recent Phase I data, and it might be up to Lilly to retore investor confidence.

Verve’s shares dropped hard on its recent Phase I data, and it might be up to Lilly to retore investor confidence.